News - Immusoft

Investors & Media

Publications & Presentations

First-in-Human Clinical Trial of Autologous Human B Cells Engineered to Express Human Iduronidase in Subjects with MPS I

May 13, 2026

ASGCT – American Society of Gene & Cell Therapy
Press Releases

Immusoft to Present Data Highlighting Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial at ASGCT 2026

May 6, 2026

Immusoft
Publications & Presentations

Advancing Pediatric CGT Clinical Trials: Scientific, Ethical, Regulatory & Practical Considerations

April 14, 2026

FDA & ARM (Alliance for Regenerative Medicine)
Publications & Presentations

Translational data from the first-in-human clinical trial of autologous human B cells engineered to express human iduronidase in subjects with MPS I

April 9, 2026

WORLDSymposium
Press Releases

Immusoft Announces Presentation of World’s First Patient Treated with an Engineered B Cell Therapy at Workshop Co-Hosted by FDA and ARM

April 8, 2026

Immusoft
Press Releases

Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine

March 30, 2026

Immusoft
Articles

From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era

February 4, 2026

BioSpace
Press Releases

Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II

January 26, 2026

Immusoft
Articles

Fast-Tracked CGT Platform Eliminates Patient Preconditioning

January 13, 2026

Genetic Engineering & Biotechnology News
Press Releases

Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease

December 15, 2025

Immusoft